1 The Alaska Native/American Indian experience of hepatitis C treatment with

2 sofosbuvir-based direct-acting antivirals

- 3
- 4 Lisa Townshend-Bulson¹, Elena Roik¹, Youssef Barbour¹, Dana Bruden², Chriss Homan¹,
- 5 Hannah Espera¹, Tim Stevenson³, Annette Hewitt¹, Wileina Rhodes¹, Jim Gove¹, Julia Plotnik¹,
- 6 Mary Snowball¹, John McGilvray⁴, Brenna C. Simons², Brian McMahon¹
- 7

8 Full affiliations

- 9 ¹Alaska Native Tribal Health Consortium, Liver Disease and Hepatitis Program, Anchorage,
- 10 Alaska, USA
- 11 ²Centers for Disease Control and Prevention, Anchorage, Alaska, USA
- 12 ³Alaska State Virology Laboratory, Anchorage, Alaska, USA
- ⁴ Southcentral Foundation, Pharmacy Department, Anchorage, Alaska, USA
- 14

15 Corresponding author:

- 16 E-mail: ltownshend@anthc.org
- 17
- /
- 18
- 19
- 20
- 21
- **Z** T
- 22

24 Abstract

25	Background. Direct-acting antiviral (DAA) drugs have been effective in the treatment of
26	chronic hepatitis C virus (HCV) infection. Limited data are available on safety, tolerability, and
27	efficacy in American Indian or Alaska Native people. We aim to evaluate the treatment
28	outcomes of sofosbuvir- based regimens for treatment of HCV in a real life setting in Alaska
29	Native/American Indian (AN/AI) people.
30	Methods. AN/AI patients within the Alaska Tribal Health System with confirmed
31	positive anti-HCV and HCV RNA, who were 18 years of age and older were included in the
32	study. Pretreatment baseline patient characteristics, treatment efficacy based on sustained
33	virologic response (SVR) 12 weeks after treatment completion, and adverse effects were
34	assessed. The following treatments were given according to the American Association for the
35	Study of Liver Diseases/Infectious Disease Society of America (AASLD/IDSA) HCV Guidance:
36	ledipasvir/sofosbuvir, sofosbuvir plus weight-based ribavirin, and sofosbuvir/velpatasvir.
37	Results. We included 501 patients with a mean age of 54.3 (range 21.3 -78.3) in the
38	study. Overall SVR was achieved in 95.2% of patients who received one of the three DAA
39	regimens. For those with cirrhosis, overall SVR was 92.8% and for those with genotype 3 91.1%
40	achieved SVR. The most common symptom experienced during treatment was headache. Joint
41	pain was found to decrease during treatment. One person discontinued sofosbuvir plus ribavirin
42	due to myocardial infarction and one discontinued sofosbuvir/velpatasvir due to urticaria.
43	Conclusions. In the real-world setting, sofosbuvir-based treatment is safe, effective, and
44	well tolerated in AN/AI patients. Sustained virologic response was high regardless of HCV
45	genotype or cirrhosis status.

- 46 Keywords Chronic hepatitis C, Alaska Native, direct acting antiviral agents, sofosbuvir,
- 47 sustained virologic response, adverse effect, AN/AI

48 Introduction

49	Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease and
50	liver-related death worldwide (1, 2). The number of chronically infected individuals globally is
51	estimated to be over 130 million (3). Moreover, most new cases of acute HCV infection are not
52	identified or reported to public health authorities because most adults and adolescents with HCV
53	do not have symptoms and are unaware of their infection (4). The U.S. Centers for Disease
54	Control and Prevention (CDC) estimates there were 41,200 new HCV infections in the United
55	States in 2016 alone (4). Chronic hepatitis C is a known risk factor for development of
56	hepatocellular carcinoma (HCC) (5). Out of 700,000 cases of HCC that occurred worldwide in
57	2008, 17 to 22% are attributable to HCV infection (6, 7).
58	The prevalence of HCV infection in the United States in 2013-2016 was reported to be
59	2.4 million cases, with over 30,000 new cases of HCC and approximately 27,000 deaths
60	registered every year (8, 9). The implementation of extended criteria for Hepatitis C screening is
61	a subject of major policy debate underscoring the rising concerns over the growing public health
62	and economic burden of HCV infection (10, 11). The first National Viral Hepatitis Action Plan
63	that aimed to eliminate hepatitis C was issued in 2011(12). It focused on hepatitis B and C
64	elimination by the year 2020 and recognized that success of the action plan could not be
65	achieved without input from non-federal stakeholders, both public and private. Since then,
66	several U.S. states implemented their own hepatitis elimination programs with ambitious goals of
67	eliminating viral hepatitis by 2030, in accordance with the World Health Organization's directive
68	on eliminating viral hepatitis (13, 14).
69	A number of studies have described the epidemiology of HCV infection among American
70	Indian or Alaska Native people (15-20). Risk factors for acquisition of HCV infection and
71	genotype (GT) distribution among AN/AI were similar to those found in the National Health and
72	Nutritional Examination Survey (17, 18). End stage liver disease (ESLD) was associated with
73	older age and alcohol usage (20). Previously we found that AN/AI people did not respond well
74	to peginterferon and ribavirin-based treatment with an overall (all GTs) SVR rate of 51% and
75	discontinuation rate of 52% (19). Genotype 3 HCV infection was associated with a high risk for
76	developing ESLD, HCC and liver-related death (18). Bruden et al (20) emphasized the need for

early hepatitis C treatment of patients with moderate fibrosis to prevent development of ESLD,
HCC and liver-related death over time.

Alaska Native and American Indian (AN/AI) communities are one of the priority
populations in the National Viral Hepatitis Elimination Plan (21). A recent study showed that
86% of AN/AI people diagnosed with HCV infection in Alaska were linked to care and
treatment in 2017 (16). Despite that, national data show AN/AI people are disproportionately
affected by hepatitis C with the highest rates of both acute HCV infection and hepatitis C-related
deaths (21).

With the advent of new direct-acting antivirals (DAAs) the HCV treatment landscape has 85 86 changed. Recent studies report higher efficacy, shorter treatment duration, and fewer side effects 87 with the inclusion of the DAA sofosbuvir into treatment regimens (22-24). Importantly, hepatitis 88 C DAA therapy has eliminated the GT dependent differences in effectiveness that were associated with interferon-based therapies. Public health experts now believe it is possible to 89 eliminate the disease. Hepatitis C elimination could have a tremendous positive effect on 90 91 improving health outcomes by preventing around 400,000 deaths worldwide from complications 92 each year (25).

93 There is ongoing discussion about whether the effectiveness of hepatitis C treatment 94 varies between racial and ethnic groups in the United States. The Liver Disease and Hepatitis 95 program (LDHP) at the Alaska Native Tribal Health Consortium (ANTHC) provides a reliable 96 setting to study disparities in hepatitis C treatment due to high rates of the disease in Alaska (26), 97 with an ongoing registry in place, and an established AN/AI HCV-infected cohort from a large 98 and diverse AN/AI population.

99 In this study we aimed to evaluate the effectiveness of sofosbuvir-based hepatitis C
100 treatment regimens and describe any differences in experience and outcome among AN/AI
101 people living in Alaska as compared to other racial and ethnic groups.

102

103 Materials and Methods

104 Study design, setting, participants and data collection

106 In 1995, the ANTHC LDHP began a hepatitis C population-based cohort study (AK-107 HEPC) to learn more about adverse outcomes of chronic HCV infection in AN/AI persons. 108 AN/AI persons residing in Alaska can receive care through the Alaska Tribal Health System 109 (ATHS), an integrated system of tribally-owned and operated health care organizations for which 110 ANTHC is the umbrella organization coordinating healthcare throughout the ATHS. The LDHP 111 operates out of the Alaska Native Medical Center (ANMC), the specialty referral hospital for the 112 ATHS located in Anchorage, Alaska. Statewide testing for HCV infection is provided at ANMC 113 for AN/AI people. All persons found to be HCV antibody (anti-HCV) positive are entered into a registry for clinical care. New positive anti-HCV tests are automatically reflexed to HCV RNA 114 testing when specimen quantity permits. Those entered into the registry are invited to join the 115 116 AK-HEPC cohort study. Sofosbuvir-based treatment for this cohort was studied from March 1, 117 2014 through September 30, 2019 in 501 patients with chronic HCV. AN/AI patients within ATHS with confirmed positive anti-HCV and HCV RNA, who 118 were 18 years of age and older, and who provided written informed consent were included in the 119 120 study. The study was approved by the Alaska Area Institutional Review Board and by two 121 Alaska Tribal Health Organizations, ANTHC and Southcentral Foundation. 122 Patients were excluded from the study if they had negative HCV RNA prior to treatment, 123 current incarceration, contraindication to taking any component of a sofosbuvir-based regimen, 124 or no indication for treatment in accordance with the American Association for the Study of 125 Liver Diseases (AASLD) and Infectious Disease Society of America (IDSA) HCV Guidance

126 (27).

127 **Ethical Considerations**

Hepatitis C treatment options were discussed with the patient prior to consenting to the
treatment study. These options included all available hepatitis C medications, not just
sofosbuvir-based drugs. This manuscript examines hepatitis C treatment and outcomes of
patients who were treated with sofosbuvir-based drugs only.

AUDIT-C alcohol screening and PHQ-9 depression screening tests were completed by patients prior to treatment start. Those with positive AUDIT-C scores (\geq 3 for women and \geq 4 for men) were counseled about hazardous drinking and offered referral to a behavioral health counselor.

137 **Treatment Regimens**

The Food and Drug Administration-approved sofosbuvir-based treatment regimens
included in this study were ledipasvir/sofosbuvir, sofosbuvir plus weight-based ribavirin, and
sofosbuvir/velpatasvir. Indications and treatment duration in accordance with prescribing
information are shown in Table 1.

Due to low numbers for comparison, those with decompensated cirrhosis treated with
sofosbuvir/velpatasvir for 24 weeks (n=1), ledipasvir/sofosbuvir for 24 weeks (n=17),
sofosbuvir/velpatasvir with ribavirin for 12 weeks (n=6), ledipasvir/sofosbuvir and ribavirin for
12 weeks (n=9), and ledipasvir/sofosbuvir and ribavirin for 24 weeks (n=4) were not included in

- this analysis.
- 147

148 Treatment protocol was the same for those who were enrolled in the study cohort and 149 those who chose not to be in the study and based on current recommendations from the 150 AASLD/IDSA HCV Practice Guidance (27). For those participants treated at other mostly rural 151 Alaska Tribal facilities, the same treatment protocol was followed except there was not a 152 requirement to complete a symptoms inventory before and during treatment. For participants 153 treated at other Alaska Tribal facilities, LDHP providers were consulted by rural tribal providers 154 for treatment recommendations.

155 Study Assessments

156 Pretreatment baseline characteristics (Table 2) and laboratory results [including: 157 complete blood count (CBC), comprehensive metabolic panel (CMP), prothrombin time with 158 international normalized ratio, HCV RNA, HCV GT, alpha fetoprotein, vitamin D, glycosylated 159 hemoglobin (HgbA1C), human immunodeficiency virus (HIV), hepatitis B core antibody (anti-160 HBc), hepatitis B surface antigen (HBsAg), hepatitis A antibody total, IL-28b genotype, and 161 pregnancy test [for women of childbearing age] were assessed. HBV DNA testing was done for 162 those who were found to be anti-HBc positive. Those who were not immune or previously 163 vaccinated for hepatitis A and B were offered the appropriate vaccine series.

Liver fibrosis was assessed by either vibration controlled transient elastography (VCTE) using FibroScan[®], serum fibrosis test, or liver biopsy. A pre-treatment VCTE was performed on all patients who were treated through the ANTHC LDHP, except for the first 7 who had begun

167 treatment prior to availability of VCTE at ANTHC. Fibrosis stage was assessed according to 168 Metavir-equivalent scoring (F0 to F4). Median VCTE level >12kPa was defined as cirrhosis. 169 A thorough health history was completed prior to treatment. This included presence or history of the following: any liver disease or cirrhosis; pulmonary disorders; cardiovascular 170 171 disease; including deep vein thrombosis and pulmonary embolism; use of acid-reducing agents 172 including proton pump inhibitors (PPIs), H2 blockers and antacids; autoimmune disorders; organ 173 transplant; cancer; current infection; high blood pressure; dyslipidemia; kidney disease; anemia; 174 current TB treatment; diabetes Type 1 or 2; HIV; seizure disorder; and mental health conditions. 175 A complete medication history, which included both prescription and over-the-counter 176 supplements, was obtained to identify any potential interactions with sofosbuvir-based drugs. 177 Participants' vaccine status for influenza, pneumonia, tetanus and Tdap, and shingles were reviewed and those who were not up-to-date on those vaccines were offered them. 178

179 The safety and tolerability of antiviral drug regimens were assessed by reviewing the 180 answers on the baseline self-reported symptoms inventory completed prior to treatment and 181 subsequent symptoms inventories which were completed monthly through the end of treatment, 182 to assess for potential adverse effects related to HCV treatment. Symptoms included in the 183 inventory were: feeling excessively tired (fatigue), flu-like illness, chills, fever, weakness, 184 trouble sleeping, headache, hair loss, dry mouth, cough, shortness of breath, decreased appetite, 185 nausea, vomiting, weight loss, heartburn or upset/sour stomach, muscle aches, joint aches, back 186 pain, itching, rash, dizziness, irritability, depression or anxiety, changes in mood/mood swings, 187 and feeling forgetful/problems concentrating.

188 Prior to treatment start, an HCV treatment agreement was signed by the patient which 189 explained the treatment process, possible side effects, drug interactions, expected efficacy, and 190 asked the patient to agree to the following:

191

Not to drink alcohol or use recreational drugs during treatment. •

- 192 Report any serious medical conditions, including heart disease, high blood pressure, • 193 diabetes, high cholesterol, rheumatoid arthritis, drug addiction, or psychiatric condition.
- 194 • Commit to taking medications as prescribed and if unable to do so to contact provider.
- 195 Protect self and others from hepatitis C by not sharing needles, drug works, razors, • 196 toothbrushes, or nail clippers, and cover cuts to prevent blood exposure.

Patients were not penalized if they broke the agreement but were encouraged to resume
adherence to it. If a patient identified as having a substance use disorder, referral to behavioral
health was offered.

Labs obtained monthly during treatment and analyzed included: HCV RNA, CBC, CMP,
HBV DNA (if HBsAg positive or if HBV DNA present in those who were anti-HBc positive

202 prior to treatment), and pregnancy test on women of childbearing age.

Treatment completion or discontinuation of medications was documented. Treatment
efficacy as determined by sustained virologic response (SVR) 12 weeks after treatment
completion was assessed using HCV RNA (COBAS(R) AmpliPrep /COBAS(R) TaqMan(R)
HCV Test Kit (Roche Molecular Systems, Inc., Pleasanton, CA). CBC, hepatic function panel
and AFP were drawn at SVR time point and VCTE was repeated to assess liver fibrosis at that
time.

One year after treatment completion, VCTE was repeated to reassess liver fibrosis.
All patients whose pre-treatment fibrosis assessment (either by VCTE, serum fibrosis test, or
liver biopsy) indicated advanced liver fibrosis (Metavir F3-F4 equivalent fibrosis) were
instructed to continue to have right upper quadrant (RUQ) ultrasound along with AFP blood test
every 6 months as surveillance for HCC.

214

215 Data Analysis

216 For the outcome of DAA treatment success rate, we calculated SVR in an intention-to 217 treat analysis and a per-protocol analysis. The intention-to-treat analysis included all persons 218 who started HCV treatment. The per-protocol analysis removed persons who discontinued 219 treatment early, regardless of their virologic response and persons who were lost to follow-up 220 with an unknown virologic response. We compared the SVR rate using a likelihood ratio χ^2 or 221 Cochran-Armitage test of trend. The high SVR rates with an associated low sample size of 222 treatment failures limited the building of multivariable logistic regression models. We used 223 forward selection with log-binomial regression. After inclusion of the most significant 224 univariate variable, no statistically significant multivariable models were found. We compared 225 alanine aminotransferase (ALT), AFP and VCTE results before and after treatment using a 226 normal or log-normal response and generalized estimating equations were used to account for 227 repeated measurements. The prevalence of side effects reported on the symptoms inventory was

compared between the start and end of treatment using generalized estimating equations logistic

regression. We used the start of treatment as the start of follow-up and the date of HCC

detection, death date, or Dec 1, 2019 as the end of follow-up for calculating HCC incidence

following treatment. Exact *P*-values were reported when sample size necessitated. All analyses

were run in SAS version 9.4 and a *P*-value < 0.05 was considered statistically significant.

233

234 **Results**

235

236 Characteristics of study participants

Characteristics of patients at baseline are shown in Table 2. The final data analysis
occurred on 501 AN/AI persons who received *sofosbuvir*-based treatment from 2014 to 2018.
Seventy-five percent of treatments were prescribed by ANTHC LDHP providers on the ANMC
campus in Anchorage; (n=378); 25% were prescribed by providers at other Alaska Tribal
facilities, following the protocol used at ANTHC LDHP except symptoms inventory was limited
to participants treated in Anchorage.

For comparison, study participants were divided into three groups based on the treatment
regimen: ledipasvir/sofosbuvir, sofosbuvir plus ribavirin, and sofosbuvir/velpatasvir.
Sofosbuvir-based treatment type and duration of treatment were determined by HCV GT, and
fibrosis status in accordance with AASLD/IDSA treatment guidance available at the time of
treatment (27).

Median age of study participants was 54.3 years, ranging from 21.3 to 78.3. The majority
of patients were GT-1a [327 (65%)]; male [272(54%)], and treatment naïve [474(95%)]. The
mean body mass index (BMI) was 28.0; 122/417 (29%) patients had a BMI greater than 30.
Advanced fibrosis occurred in 134/497 (27%) persons and 69/497 (14%) patients had cirrhosis
(F4). HCV RNA greater than six million international units/ml was observed in 92/501 (18%)
patients.
Of the 501 persons, 480 (96%) completed their treatment regimen. Twenty percent

(93/460) of persons were anti-HBc positive prior to sofosbuvir-based treatment; with 4 of those
having chronic hepatitis B (HBsAg positive). Four participants who reported ongoing injection
drug use had achieved SVR and then had HCV RNA detected at a later time point, suggesting

reinfection. Eight patients (2%) were HIV positive. There were no positive pregnancy testsduring the study.

260

261 Therapeutic Response for Sofosbuvir-based Treatment in AN/AI

262 **People**

263 Sofosbuvir-based medication consisted of ledipasvir/sofosbuvir (n=-348),

sofosbuvir/velpatasvir (n=94), and sofosbuvir plusribavirin (n=59). The most frequent treatment

length was 12 weeks (74%), followed by 8 weeks (22%), 24 weeks (3%), and 16 weeks (1%).

266 SVR was analyzed for both intention-to-treat and per-protocol groups in Table 3.

267 First, we looked at SVR in the intention-to-treat analysis. Overall SVR rate for 268 sofosbuvir-based treatment was 95.2% (477/501); for the patients treated at ANMC, SVR was 269 95.8% versus 93.5% at other Alaska locations. This was not statistically significant. Females did 270 not differ in treatment success compared with males (P=0.09). Patients who completed treatment 271 had significantly higher treatment success compared to those who did not finish treatment 272 (P < 0.0001). Those with cirrhosis responded as well to treatment as those without cirrhosis. 273 Additionally, there were no significant differences in treatment success by age, HCV GT, IL-28b 274 GT, use of acid-reducing agent, anti-HBc positive status, or having undergone a previous HCV

treatment.

276 We next looked at SVR per-protocol (removing those who discontinued treatment and persons lost to follow up following treatment completion). These exclusion criteria reduced the 277 278 analysis cohort to 479 persons. Overall treatment success improved to 97.3% (466/479). SVR 279 was significantly higher for patients treated at ANMC compared to other Alaska locations 280 (P=0.02). Fibrosis level at treatment start became significant to treatment success (p<0.01) in the 281 per-protocol analysis. Age, sex, HCV GT, IL-28b status, or acid-reducing agent use remained 282 non-significant. Higher SVR rate of those without presence of cirrhosis was significant 283 (P=0.002) as compared to those with compensated cirrhosis. Also, those who had not undergone 284 previous HCV treatment had a significantly higher SVR rate (P=0.03) compared to those who 285 had been previously treated.

Eleven persons developed HCC after their treatment (range of 3 months to 3.7 years after treatment); all had F3 to F4 fibrosis prior to treatment. HCC incidence following DAA treatment was 6.37 cases per 1000 person-years of follow-up.

- 289 There were four HCV re-infections (<1%) that occurred in participants who had achieved 290 SVR. All four were found to have a different GT, and had known continued injection drug use. 291 Having resolved hepatitis B infection, isolated anti-HBc positive, or chronic hepatitis B (HBsAg-292 positive) did not affect SVR rate in our AN/AI cohort. Also, there were no flares of hepatitis B 293 (defined as elevated ALT >2 ULN and HBV DNA > 2,000 IU/mL in persons with previously 294 inactive or resolved HBV) among those who were anti-HBc+ (28), including those with chronic 295 hepatitis B during treatment. There was one death while on HCV treatment due to non-liver 296 related cancer, and two deaths of unknown cause following HCV treatment completion but prior 297 to SVR time point.
- 298

299 Changes in Treatment Characteristics from Pre to Post Treatment

We investigated changes in ALT, AFP, and VCTE fibrosis score pre to post treatment for
those at ANMC only. All characteristics explored were significant regardless of SVR (Table 4).
Treatment success led to reduced AFP levels post treatment and significant reductions in fibrosis
scores by VCTE 1-2 years after treatment.

304

305 Side Effects

306 Changes in the prevalence of adverse effects, collected through the symptoms inventory, 307 between week 0 and the end of treatment, were analyzed by treatment regimen from the patients 308 treated at ANMC (Table 5). Persons who received sofosbuvir plus ribavirin experienced an increase in mood changes (P=0.040), shortness of breath (P=0.003), and dizziness (P=0.040). 309 310 Those who received ledipasvir/sofosbuvir reported only an increase in headache (P=0.004) on 311 treatment, and those who received sofosbuvir/velpatasvir did not show any statistically 312 significant increases in symptoms during treatment. There was one person who discontinued 313 treatment after one day taking sofosbuvir/velpatasvir because of urticaria. One person 314 discontinued sofosbuvir plus ribavirin after hospitalization for non-ST segment elevation 315 myocardial infarction secondary to coronary vasospasm.

Conversely, after SVR there was a reported significant decrease in joint pain by participants receiving any of the three regimens. Those who received sofosbuvir + ribavirin and ledipasvir/sofosbuvir reported a significant decrease in back pain. Those who received sofosbuvir/velpatasvir reported less depression (P=0.02) and less decreased appetite (P<0.01). Additionally, those who were treated with ledipasvir/sofosbuvir regimens reported significant decreases in trouble sleeping (P=0.020), joint pain (P=0.001), back pain (P=0.002), and muscle pain (P=0.040).

323

324 **Discussion**

In this sofosbuvir-based treatment study of AN/AI patients with HCV, overall SVR was
achieved by 95.2% of participants. These SVR rates are comparable to rates found in other
ethnic groups (29, 30). There were no statistically significant differences in SVR rate by HCV
GT, IL-28 GT, or acid blocker use. Sofosbuvir-based HCV treatment regimens were effective
and tolerated well by AN/AI persons.

330 The introduction of all-oral sofosbuvir therapeutic regimens for the treatment of chronic 331 hepatitis C has led to remarkable improvement in SVR, providing therapeutic options to patients 332 with contraindications to IFN-based regimens as well as those who either failed or were 333 intolerant to IFN. However, despite the more convenient dosing schedules and shorter durations 334 of treatment and high cure rates, a small percentage of patients experience treatment failure. The 335 SVR results of our study are in line with earlier studies reporting SVR rates between 87% and 336 99% (29, 31-34). Furthermore, 92.8% of patients with compensated cirrhosis achieved SVR. The 337 SVR rate for cirrhosis patients achieved in our study is similar to those reported in phase 2 and 3 338 clinical trials (35, 36).

We assume the high SVR rate of 97.3% in those who completed the study per-protocol was achieved due to high adherence rate and close monitoring and follow-up by experienced nurses and health care providers.

In our study the decreases in non-invasive serological markers (ALT, AFP) and VCTE
fibrosis scores suggest a significant regression of inflammation and liver fibrosis in patients at
SVR12 as compared to baseline. Several studies have shown the same results; however, the
effect was more pronounced in patients with baseline VCTE scores suggesting advanced stages

of fibrosis and cirrhosis (37, 38). However, the findings of decreases in liver stiffness scores
might be influenced by inflammation, resulting in lower kPa measurements after SVR, which has
been previously found in patients with chronic hepatitis (39).

349 Hepatitis due to reactivation of HBV infection during treatment with DAAs for chronic 350 HCV infection has been reported in patients who were anti-HBc+ prior to treatment. In general, 351 an HBV flare is defined as elevated ALT and HBV DNA > 2,000 IU/mL in persons with 352 previously inactive or resolved HBV infection. Findings from Loggi et al. (40) on 44 subjects 353 who received DAA treatment for HCV infection, found no reactivation in those with past HBV 354 infection (anti-HBc+ only). They also found that two persons who were HBsAg-positive 355 experienced a flare of HBV infection, followed by HBsAg loss. Another study showed that 356 hepatitis B reactivation was a rare event in anti-HBc+/HBsAg-negative patients treated with 357 DAA therapy (41). In our study there were a large number of anti-HBc+ patients (93). Eighty 358 nine of these patients were anti-HBc+/HBsAg-negative whom we assume were infected with 359 hepatitis B and recovered shortly after, and 4 patients were HBsAg-positive, having chronic 360 hepatitis B coinfection. None of these 93 patients experienced flares of HBV during or 361 immediately following treatment. This finding adds support to the body of knowledge showing 362 hepatitis B flares, among those chronically infected and reactivation among those with resolved 363 infection, as a result of HCV treatment, is rare.

364 HCV reinfection following successful treatment can compromise treatment outcomes. In
365 our study population, we observed less than 1 percent reinfection rate due to ongoing drug use in
366 those who achieved SVR during the span of the study follow up period. A recent meta-analysis
367 showed an overall rate of HCV reinfection of 5.9/100 person-years (95% CI 4.1-8.5) among
368 people with recent drug use (injecting or non-injecting), and 6.2/100 person-years (95% CI 4.3369 9.0) among people recently injecting drugs (42).

In our study none of the participants experienced serious adverse effects. The symptoms
that increased in frequency were: headache for *ledipasvir/sofosbuvir*, and changes in mood,

372 shortness of breath, and dizziness on *sofosbuvir* plus *ribavirin*, which is likely due to ribavirin.

373 That is in line with previous studies (36, 43-45). Mizokami et al (46) data shows that the most

374 common adverse effects on sofosbuvir-based treatment are nasopharyngitis, anemia, headache

and malaise. Difference in the results may be partially explained by the differences in inherent

376 metabolic pathways and different drug-drug interactions.

- Our study adds to the body of evidence regarding successful hepatitis C treatment among
 racial minorities, specifically AN/AI people. It is the largest study to date of American Indian or
 Alaska Native persons with hepatitis C treated with DAAs (47).
- Limitations of our study are that the cohort includes only AN/AI persons, therefore our
 findings may not apply to other racial/ethnic groups. However, this cohort was described
 previously and found to closely represent the US population infected with HCV in terms of HCV
 GT distribution and risk factors for infection (17).
- 384 Treatment of HCV infection does not only benefit those infected but also reduces the 385 burden of hepatitis C at the population level (2). Regardless of stage of liver disease, coinfection, or complications there is a survival benefit of SVR (2). Cure of HCV infection has a long term 386 387 impact on the economic burden of disease (48). Complications of HCV infection such as liver 388 cirrhosis, HCC and transplantation are associated with high medical cost and use of healthcare 389 resources (49). From a public health perspective, the "treatment as prevention" model as 390 undertaken by ANTHC LDHP is of great benefit. It may reduce the prevalence of HCV 391 infection in the population in the long-term, leading to a lower transmission rate and incidence of 392 disease. To achieve 2030 targets of a 90% reduction in new cases of HCV infection and a 65% 393 reduction in liver-related death, a new capacity for screening and treatment should be built. 394 Hepatitis C needs to become a disease of high priority in both clinical and public health settings.
- 395

396 **Conclusion**

397 Our treatment study with sofosbuvir-based regimens was effective for a broad range of 398 AN/AI patients with HCV GT 1, 2, 3, 4, or 6 infection. The treatment was also effective among 399 patients with cirrhosis. These real-life study findings, in a population not included in pre-400 licensure clinical trials, suggest that HCV treatment for AN/AI persons should lead to a long-401 term decrease in liver disease progression and prevention of the development of HCC and 402 reduction in disparities of HCV liver disease for AN/AI people.

To date, over 1000 AN/AI persons in Alaska have been treated through the ATHS and cured of hepatitis C with DAA therapy. However, there remains another 1000 known AN/AI persons in Alaska with hepatitis C including approximately 180 AN/AI persons living in over 100 isolated communities without primary care providers and not connected to the road system.

407	Moving forward, the use of telemedicine and other innovative ways to test and treat HCV are
408	being explored so that all AN/AI people can access antiviral treatment, disparities in liver disease
409	outcomes can lessen, and the overarching goal of HCV elimination can be met in the AN/AI
410	population.
411	
412	Conflict of Interest
413	This study was funded in part by Gilead Sciences.
414	
415	Disclaimer
416	Dana Bruden is employed by the CDC. The findings and conclusions in this study are those of
417	the authors and do not necessarily represent the official position of the CDC.
418	
419	
420	
421	
422	
423	
424	

426 **References**

- 427 1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17(2):107-15.
- 428 2. WHO. Global Hepatitis Report 2017 [Available from:
- 429 <u>https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-</u>
- 430 <u>eng.pdf;jsessionid=57E13E6157F27DF0909272374DB84FAA?sequence=1</u>.
- 431 3. Mohamed AA, Elbedewy TA, El-Serafy M, El-Toukhy N, Ahmed W, Ali El Din Z. Hepatitis C virus: A
 432 global view. World J Hepatol. 2015;7(26):2676-80.
- 433 4. CDC. Surveillance for Viral Hepatitis United States, 2016 2016 [Available from:
- 434 https://www.cdc.gov/hepatitis/statistics/2016surveillance/commentary.htm.
- 435 5. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology.
- 436 2012;142(6):1264-73 e1.
- 437 6. WHO. Liver Cancer. Keyfacts. 2008 [Available from:
- 438 <u>https://www.who.int/cancer/resources/keyfacts/en/</u>.
- 439 7. WHO. Liver Cancer. 2018 [Available from: <u>https://www.who.int/hepatitis/news-events/world-</u>
 440 cancer-day/en/.
- 441 8. Hofmeister MG, Rosenthal EM, Barker LK, Rosenberg ES, Barranco MA, Hall EW, et al. Estimating
 442 Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016. Hepatology. 2019;69(3):1020-
- 443 31.
- 444 9. CDC. Liver cancer. Facts. 2019 [Available from: <u>https://www.cdc.gov/cancer/liver/index.htm</u>.
- 445 10. Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic Manifestations of Hepatitis
 446 C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology.
- 447 2016;150(7):1599-608.
- 448 11. Younossi ZM, Tanaka A, Eguchi Y, Lim YS, Yu ML, Kawada N, et al. The impact of hepatitis C virus
 449 outside the liver: Evidence from Asia. Liver Int. 2017;37(2):159-72.
- 450 12. HHS. National Viral Hepatitis Action Plan 2011. 2011 [Available from:
- 451 https://www.hhs.gov/sites/default/files/action-plan-viral-hepatitis-2011.pdf.
- 452 13. Department of Health WS. Plan to Eliminate Hepatitis C in Washington State by 2030 2019
- 453 [Available from: <u>https://www.doh.wa.gov/Portals/1/Documents/Pubs/150nonDOH-HepCFreeWA-</u>
 454 PlanJuly2019.pdf.
- 455 14. Department of Health NYS. New York State Hepatitis C Elimination Task Force 2019 [Available 456 from: https://www.health.ny.gov/diseases/communicable/hepatitis/hepatitis c/elimination.htm.
- 457 15. McMahon BJ, Bruden D, Bruce MG, Livingston S, Christensen C, Homan C, et al. Adverse
- 458 outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. Gastroenterology.
 459 2010;138(3):922-31 e1.
- 460 16. McMahon BJ, Townshend-Bulson L, Homan C, Gounder P, Barbour Y, Hewitt A, et al. Cascade of
- 461 Care for Alaska Native People with Chronic Hepatitis C Virus Infection: Statewide Program with High462 Linkage to Care. Clin Infect Dis. 2019.
- 463 17. McMahon BJ, Hennessy TW, Christensen C, Bruden D, Sullivan DG, Homan C, et al. Epidemiology
 464 and risk factors for hepatitis C in Alaska Natives. Hepatology. 2004;39(2):325-32.
- 465 18. McMahon BJ, Bruden D, Townshend-Bulson L, Simons B, Spradling P, Livingston S, et al. Infection
 466 With Hepatitis C Virus Genotype 3 Is an Independent Risk Factor for End-Stage Liver Disease,
- 467 Hepatocellular Carcinoma, and Liver-Related Death. Clin Gastroenterol Hepatol. 2017;15(3):431-7 e2.
- 468 19. Livingston SE, Townshend-Bulson LJ, Bruden DJ, Homan CE, Gove JE, Plotnik JN, et al. Results of
- interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C.
- 470 Int J Circumpolar Health. 2016;75:30696.

471 20. Bruden DJT, McMahon BJ, Townshend-Bulson L, Gounder P, Gove J, Plotnik J, et al. Risk of end-472 stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C 473 Alaska Cohort. Hepatology. 2017;66(1):37-45. 474 21. HHS. National Viral Hepatitis Plan 2017-2020. 2017 [Available from: 475 https://www.hhs.gov/hepatitis/action-plan/national-viral-hepatitis-action-plan-overview/index.html. 476 22. Gentile I, Borgia F, Zappulo E, Buonomo AR, Spera AM, Castaldo G, et al. Efficacy and Safety of 477 Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era. Rev Recent Clin Trials. 478 2014;9(1):1-7. 479 23. Afdhal NH. A Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Hepatitis C Virus 480 Genotype 1. Gastroenterol Hepatol (N Y). 2014;10(12):815-7. 481 24. Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Puoti M, Orkin C, et al. Sofosbuvir and 482 Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The 483 Impact on Patient-Reported Outcomes. J Infect Dis. 2015;212(3):367-77. 484 WHO. Hepatitis C. Key Facts. 2019 [Available from: https://www.who.int/news-room/fact-25. 485 sheets/detail/hepatitis-c. 486 Gounder PP, Koch A, Provo G, Lovlie A, Ederth JL, Axelsson M, et al. Summary of available 26. 487 surveillance data on hepatitis C virus infection from eight Arctic countries, 2012 to 2014. Euro Surveill. 488 2018;23(40). 489 27. America AAftSoLDaIDSo. HCV Guidance: Recommendations for Testing, Managing, and Treating 490 Hepatitis C 2014-2018 [Available from: hcvguidelines.org. 491 28. AASLD. AASLD guidelines for treatment of chronic hepatitis B 2015 [Available from: 492 https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.28156. 493 29. Gayam V, Tiongson B, Khalid M, Mandal AK, Mukhtar O, Gill A, et al. Sofosbuvir based regimens 494 in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-495 based retrospective cohort study. Eur J Gastroenterol Hepatol. 2018;30(10):1200-7. 496 30. Su F, Green PK, Berry K, Ioannou GN. The association between race/ethnicity and the 497 effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology. 2017;65(2):426-38. 498 31. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and 499 ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993-2001. 500 32. Younossi ZM, Stepanova M, Marcellin P, Afdhal N, Kowdley KV, Zeuzem S, et al. Treatment with 501 ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 502 clinical trials. Hepatology. 2015;61(6):1798-808. 503 33. Esteban R, Pineda JA, Calleja JL, Casado M, Rodriguez M, Turnes J, et al. Efficacy of Sofosbuvir 504 and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and 505 Cirrhosis. Gastroenterology. 2018;155(4):1120-7 e4. 506 34. Alonso S, Riveiro-Barciela M, Fernandez I, Rincon D, Real Y, Llerena S, et al. Effectiveness and 507 safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection 508 and cirrhosis. Results of a multicenter real-life cohort. J Viral Hepat. 2017;24(4):304-11. 509 35. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment 510 with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III 511 study. Hepatology. 2015;61(4):1127-35. Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, et al. Daclatasvir, sofosbuvir, and 512 36. 513 ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-514 3+). Hepatology. 2016;63(5):1430-41. 515 37. Sung JC, Bosh C, Wyatt B, Miller M, Harty A, Del Bello D, et al. Hepatitis C cure improved patient-516 reported outcomes in patients with and without liver fibrosis in a prospective study at a large urban 517 medical center. J Viral Hepat. 2019.

518 38. Lledo GM, Carrasco I, Benitez-Gutierrez LM, Arias A, Royuela A, Requena S, et al. Regression of
519 liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV
520 coinfection. AIDS. 2018;32(16):2347-52.

39. Zeng X, Xu C, He D, Zhang H, Xia J, Shi D, et al. Influence of Hepatic Inflammation on FibroScan
Findings in Diagnosing Fibrosis in Patients with Chronic Hepatitis B. Ultrasound Med Biol.

523 2015;41(6):1538-44.

40. Loggi E, Gitto S, Galli S, Minichiello M, Conti F, Grandini E, et al. Hepatitis B virus reactivation
among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice. J Clin
Virol. 2017;93:66-70.

- 527 41. Feld JJ, Maan R, Zeuzem S, Kuo A, Nelson DR, Di Bisceglie AM, et al. Effectiveness and Safety of
 528 Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study.
 529 Clin Infect Dis. 2016;63(6):776-83.
- 42. Younossi ZM, Park H, Gordon SC, Ferguson JR, Ahmed A, Dieterich D, et al. Real-world outcomes
 of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. Am J Manag Care. 2016;22(6 Spec
 No.):SP205-11.
- 43. Lawitz E, Poordad F, Gutierrez JA, Kakuda TN, Picchio G, Beets G, et al. Simeprevir, daclatasvir
- and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease. J Viral Hepat.
 2017;24(4):287-94.
- 44. Poordad F, Lawitz E, Gutierrez JA, Guerrero J, Speeg K, Swenson ES. An HCV-positive recipient of
 an HCV-positive donor liver successfully treated before and immediately after liver transplant with
 daclatasvir, sofosbuvir, and ribavirin. Clin Case Rep. 2017;5(4):371-5.
- 53945.Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and540dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973-82.
- 46. Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15(6):645-53.
- 47. Mera J, Joshi K, Thornton K, Box T, Scott J, Sedillo M, et al. Retrospective Study Demonstrating
 High Rates of Sustained Virologic Response After Treatment With Direct-Acting Antivirals Among
 American Indian/Alaskan Natives. Open Forum Infect Dis. 2019;6(7):ofz128.
- 548 48. Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a 549 systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis. 2015;15:19.
- 50 49. El Khoury AC, Klimack WK, Wallace C, Razavi H. Economic burden of hepatitis C-associated
- diseases in the United States. J Viral Hepat. 2012;19(3):153-60.
- 552

554 Table 1. Treatment Regimens of 501 AN/AI persons treated for hepatitis C in Alaska using

555 sofosbuvir-based Direct Acting Antivirall therapy, Alaska (2014-2018).

Treatment Regimen	Duration of treatment	Indication
	and sample size	
Ledipasvir/sofosbuvir	8 weeks	GT 1 without cirrhosis and HCV viral load < 6
	(n =110)	million international units/mL could be given for a
		shortened course of 8 weeks, in accordance with
		prescribing information and at the discretion of the
		prescribing provider
Ledipasvir/sofosbuvir	12 weeks	GT 1,4,5,and 6 patients who were treatment naïve
	(n =238)	without cirrhosis or with compensated cirrhosis or
		GT 1,4,5, and 6 patients without cirrhosis who had
		previously been treated with interferon-based
		treatment
Sofosbuvir plus	12 weeks	GT 2 without cirrhosis. Used until
ribavirin	(n = 39)	sofosbuvir/velpatasvir became available in Aug 2016
Sofosbuvir plus	16 weeks	GT 2 with cirrhosis or previously treated with
ribavirin	(n = 6)	interferon-based treatment. Used until
		sofosbuvir/velpatasvir became available in Aug 2016
Sofosbuvir plus	24 weeks	GT 3 regardless of cirrhosis status. Used until
ribavirin	(n = 14)	sofosbuvir/velpatasvir became available in Aug 2016
Sofosbuvir/velpatasvir	12 weeks	All GTs without cirrhosis or with compensated
	(n = 94)	cirrhosis starting in Aug 2016

556

Table 2. Characteristics of 501 AN/AI persons treated for hepatitis C in Alaska using sofosbuvirbased DAA therapy, Alaska (2014-2018).

based DAA therapy, Ala	iska (2014-2018).		
Characteristic	Level	All Persons	Persons Treated at
		% (n = 501)	ANMC
			% (n = 378)
Treatment Location	ANMC	75% (378)	100% (378)
	Non-ANMC	25% (123)	
Completed Therapy		96% (482)	95% (360)
Previously treated		5% (27)	6% (22)
IL28b	CC	45% (145)	45% (120)
(n - 22C)	СТ	46% (151)	46% (124)
(n= 326)	TT	9% (30)	9% (25)
Known HIV Positive		2% (8)	1% (5)
	8 Weeks	22% (109)	22% (84)
Treatment Length	12 Weeks	74% (372)	74% (279)
	16 Weeks	1% (6)	1% (4)
	24 Weeks	3% (14)	3% (11)
	Sofosbuvir+Ribavirin	12% (59)	12% (45)
Treatment Regimen	Ledipasvir/Sofosbuvir	70% (348)	67% (252)
	Sofosbuvir/Velpatasvir	18% (94)	21% (81)
	1a	65% (327)	64% (242)
HCV GT	1b	10% (52)	10% (39)
	2	15% (75)	16% (59)
	3	9% (45)	10% (37)
	4,6	0.4% (1 each)	0.3% (1 GT 6)
Female Gender		46% (229)	47% (177)
PPI/Antacid Use ^a		29% (96/335)	29% (95/331)
·	Characteristics at Star	t of Treatment	
Median Age (range)		54.3 Years (21.3,	52.3 years (22.3, 72.7
Mean BMI		28.0	28.1
% BMI ≥ 30		29% (122/417)	30% (106/356)
Advanced Fibrosis (F3-F4)		27% (134/497)	22% (84)
Cirrhosis (F4)		14% (69/497)	13% (49)
Median ALT (min, max) at		52 (7, 612)	51 (7, 612)
HCV RNA \geq 6 million ^b		18% (92)	20% (76/378)
Vitamin D < 30 iu/mL ^b		45% (185/415)	45% (153/341)
Vitamin D < 20 iu/mL ^b		15% (64/415)	15% (50/341)
Mean A1C % (min, max) ^b		5.6 (4.4, 11.6)	5.4 (4.4, 11.6)
Median AFP ^b		3.6 (0.6, 226.1)	3.4 (0.6, 226.1)
Median AFP ^b Median GFR (mL/min) ^b		3.6 (0.6, 226.1) 94 (38, 257)	3.4 (0.6, 226.1) 98 (38, 257)

^a – Defined as use of any PPI, H2 blocker, or magnesium or aluminum containing antacid.

561 b – These labs were collected between 24 weeks prior to treatment start until one week after treatment start. The closest

562 chronologically to the treatment start date was used in calculation of mean or median.

563 ^c – At any time point prior to treatment

567able 3. Treatment success results among AN/AI (sustained virologic response at 12 weeks post 566ceatment) by Intention-to-treat and Per-protocol Analyses with 95% Confidence Intervals [CI], 5607aska, 2014-2018

Category	Level	SVR Intention-to-treat	<i>P</i> -valuefor Difference	SVR Per-protocol ^a	<i>P</i> -value for Difference	
Overall		95.2% [93.3, 97.1]		97.3% [95.8, 98.7]		
Sex	Female	96.9% [93.8, 98.8]	0.09	98.2% [95.4, 99.5]	0.26	
Sex	Male	93.8% [90.9, 96.6]	0.09	96.5% [94.3, 98.8]	0.20	
	< 40 years	93.3% [89.7, 98.7]		99.0% [94.3, 99.9]		
Age	40-59 years	95.9% [93.6, 98.3]	0.95	97.3% [95.3, 99.3]	0.18	
	≥ 60 years	94.5% [90.6, 98.5]		96.0% [92.5, 99.4]		
	Pre 1966	95.0% [92.6, 97.4]		96.4% [94.3, 98.5]		
Birth Cohort	After 1966	95.6% [92.6, 98.6]	0.75	98.8% [95.9, 99.9]	0.15	
Treatment	ANMC	95.8% [93.7, 97.8]	0.00	98.3% [96.4, 99.4]	0.00	
Location	Rural	93.5% [89.1, 97.9]	0.32	94.2% [88.4, 97.6]	0.02	
Completed	Yes	97.9% [96.0, 99.1]		Not Applicable		
Treatment	No	54.6% [32.2, 75.6]	<0.0001	Not Applicable		
- · ·	Led/Sof ^b	96.8% [95.0, 98.7]		97.9% [96.4, 99.4] ^d		
Treatment	Sof/Riba	86.4% [77.7, 95.2]	0.004 ^c	90.6% [82.7, 98.4]	0.01 ^c	
Regimen	Sof/Vel	94.6% [88.0, 98.3]		98.9% [94.0, 100.0]		
	Yes	92.6% [88.0, 97.3]		94.0% [89.7, 98.3]		
BMI ≥ 30	No	96.3% [94.1, 98.4]	0.13	98.6% [96.4, 99.6]	0.02	
Steatosis (CAP	Yes	92.8% [88.7, 96.9]		94.6% [91.0, 98.2]		
> 248)	No	97.0% [94.3, 99.6]	0.09	98.7% [99.5, 99.9]	0.05	
	Yes	94.6% [86.7, 98.5]	0.76	97.2% [90.3, 99.7]		
A1c ≥ 5.7	No	95.5% [93.1, 97.9]		97.8% [96.0, 99.5]	1.00	
0	Yes	93.6% [88.6, 98.5]	0.40	93.3% [88.2, 98.5]		
Hep B Core + ^e	No	95.9% [93.9 <i>,</i> 97.9]		98.3% [96.9, 99.7]	0.08	
	F0-F1	96.1% [93.9, 98.4]		99.3% [97.4, 99.9]		
	F2	96.2% [89.2, 99.2]		97.4% [90.8, 99.7]	£	
Fibrosis Level	F3	92.3% [83.0, 97.5]	0.13	93.4% [84.1, 98.2]	0.002 ^f	
	F4	92.8% [83.9, 97.6]		92.7% [83.7, 97.6]		
	1a	95.1% [92.7, 97.4]		97.4% [95.0, 98.9]		
HOVET	1b	100.0% [93.2, 100.0]	0.14	100.0% [93.0, 100.0]	0.38	
HCV GT	2	94.7% [86.9, 98.5]		95.9% [88.5, 99.1]		
	3	91.1% [78.8, 97.5]		95.1% [83.5, 99.4]		
	≥ 6 million	92.4% [87.0, 97.8]	0.20	95.4% [88.5, 98.7]	0.26	
HCV RNA Level	< 6 million	95.8% [93.9, 97.8]	0.28	97.7% [96.2, 99.2]	0.26	
11 29h	CC	97.9% [94.1, 99.6]	0.22	98.6% [95.0, 99.8]	0.15	
IL-28b	СТ	94.0% [90.3, 97.8]	0.22	95.2% [91.7, 98.7]	0.15	

	TT	93.3% [77.9, 99.2]		100.0% [87.2, 100.0]	
Compensated	Yes	92.8% [83.9, 97.6]	0.20	92.7% [83.7, 97.6]	0.02
Cirrhosis	No	95.6% [93.6 <i>,</i> 97.5]	0.36	98.0% [96.7, 99.4]	0.03
pour g	Yes	92.5% [83.4, 97.5]	0.25	96.8% [89.0, 99.6]	0.00
PPI Use ^g	No	95.6% [93.7, 97.6]	0.35	97.4% [95.8, 98.9]	0.68
Treatment	Yes	95.6% [93.7, 97.4]	0.12	97.8% [96.4, 99.2]	0.02
Naive	No	88.9% [70.8, 97.7]	0.13	88.5% [69.9, 97.6]	0.03

568 ^a – Persons Discontinuing Treatment Were Removed and Persons with Unknown SVR

569 ^b – *P*-value for Ledsof 8-week (99.1%, 108/109) vs. Ledsof 12-week (95.8%, 229/239) treatment = 0.18

570 ^c – *P*-value is for Led/Sof and Sof/Vel vs. Sof/Riba

571 ^d – *P*-value for Ledsof 8-week (99.1%, 108/109) vs. Ledsof 12-week (97.4%, 221/227) treatment = 0.44

572 ^e – all 4 persons who were positive for HBsAg responded with an SVR at 12 weeks

573 ^f – *P*-value for F0-F1-F2 vs. F3-F4 :

574 ^g – 67 persons with omeprazole

575

577 Table 4. Changes in Fibrosis Markers Among AN/AI Pre and Post Treatment for Persons ^a

578 Treated with Sofosbuvir-Based DAAs at ANMC^{b,} Alaska, 2014-2018.

Variable	Cohort	Pre Treatment ^c	Post Treatment ^d	P-value	Post Treatment 2 ^e
Median ALT ^f	Among All	51.0 (7, 612) (n = 379)	16.0 (4, 120) (n = 334)	< 0.0001	
Median ALI	Success SVR	51.0 (7, 612) (n = 352)	16.0 (4, 120) (n = 313)	< 0.0001	
Median AFP ^g	Among All	3.4 (0.6, 226.1) (n = 378)	3.0 (0.9 <i>,</i> 440.7) (n = 283)	< 0.0001	
	Success SVR	3.4 (0.6, 87.9) (n = 351)	3.0 (0.9 <i>,</i> 440.7) (n = 265)	< 0.0001	
	F0-F1	3.0 (0.6, 14.1) (n = 240)	2.8 (1.0, 14.4) (n = 177)	0.0004	
Median AFP (Among All)	F2	3.5 (0.7 <i>,</i> 22.5) (n = 54)	3.2 (0.9, 9.4) (n = 39)	0.008	
	F3-F4	6.3 (1.7, 226.1) (n = 84)	3.7 (1.6, 440.7) (n = 67)	<0.0001	
Median AFP	F0-F1	3.0 (0.6, 14.1) (n = 223)	2.7 (1.0, 14.4) (n = 167)	<0.0001	
(Among those who achieved	F2	3.5 (0.7, 22.5) (n = 52)	3.2 (0.9, 9.4) (n = 38)	0.005	
SVR)	F3-F4	6.3 (1.7 <i>,</i> 87.9) (n = 76)	3.6 (1.6, 440.7) (n = 60)	<0.0001	
VCTE ^h	Among All	5.7 (2.3, 46.4) (n = 308)	5.1 (2.3 <i>,</i> 75.0) (n = 291)	<0.0001	
VCIE	Success SVR	5.8 (2.3, 46.4) (n = 289)	5.1 (2.3 <i>,</i> 75.0) (n = 283)	0.02	5.0 (2.7, 48) (n = 209)
	F0-F1	5.1 (2.3, 10.4) (n = 200)	4.6 (2.3, 21.3) (n = 180)	0.03	
VCTE (Among All)	F2	7.6 (3.0, 12.5) (n = 49)	5.3 (2.7 <i>,</i> 12.1) (n = 45)	<0.0001	
	F3-F4	11.9 (4.5 <i>,</i> 46.4) (n = 59)	9.4 (3.3 <i>,</i> 75.0) (n = 66)	<0.0001	
VCTE	F0-F1	5.1 (2.3, 7.9) (n = 186)	4.6 (2.3, 21.3) (n = 175)	0.03	4.6 (2.7, 19.0 (n = 125)
(Among those who achieved	F2	7.6 (3.0, 12.5) (n = 47)	5.3 (2.7, 12.1) (n = 45)	<0.0001	4.6 (2.9, 9.5) (n = 27)
SVR)	F3-F4	12.1 (4.5, 46.4) (n = 56)	8.8 (3.3, 75.0) (n = 63)	<0.0001	7.4 (4.1, 48.0 (n = 57)

579 ^a - n=378

580 ^b - Alaska Native Medical Center

581 ^c- from 6 weeks prior to treatment start to 1 week after treatment start

582 ^d – from 12-36 weeks after treatment stopped

583 ^e – from 1 years to < 2 years post therapy

584 ^f - ALT = alanine aminotransferase

585 ^g – AFP = alpha fetoprotein

586 h – VCTE = vibration controlled transient elastography

Table 5. Symptoms Experienced According to Hepatitis C Treatment Regimen among an Alaska
 Native/American Indian Cohort^a 2014-2018,

Side Effect	Treatment		Drug Regimen	
b	Week	Sofosbuvir/Ribavirin	Ledipasvir/Sofosbuvir	Sofosbuvir/Velpatasvir
		(n= 45)	(n = 252)	(n = 81)
	0	41% (18/44)	35% (87/246)	51% (37/73)
Tired	End of	41% (15/37)	33% (73/221)	43% (30/69)
	Treatment			
P-value	•	0.95	0.54	0.37
	0	16% (7/44)	26% (64/246)	25% (18/73)
Headache	End of	22% (8/37)	36% (79/221)	25% (17/69)
	Treatment			
P-value		0.24	0.004 个	0.86
Traubla	0	36% (16/44)	43% (106/246)	42% (31/73)
Trouble	End of	49% (18/37)	35% (78/221)	38% (26/69)
Sleeping	Treatment			
P-value		0.38	0.02 🗸	0.58
	0	52% (23/44)	44% (109/246)	51% (37/73)
Joint Pain	End of	27% (10/37)	32% (70/221)	38% (26/69)
	Treatment			
P-value		0.009 🗸	0.001 ↓	0.04 ↓
Back Pain	0	45% (20/27)	44% (107/246)	55% (40/73)
	End of	22% (8/37)	33% (72/221)	42% (29/69)
	Treatment			
P-value	•	0.01 ↓	0.002 ↓	0.06
Muscle	0	32% (14/44)	39% (96/246)	42% (31/73)
Pain	End of	24% (9/37)	31% (69/221)	33% (23/69)
raili	Treatment			
P-value		0.27	0.04 🗸	0.21
	0	23% (10/44)	31% (76/246)	32% (23/73)
Forgetful	End of	32% (12/37)	25% (56/221)	28% (19/69)
	Treatment			
P-value		0.30	0.12	0.64
	0	18% (8/44)	24% (59/246)	15% (11/73)
Dry Mouth	End of	24% (9/37)	24% (54/221)	22% (15/69)
	Treatment			
P-value		0.39	0.76	0.14
	0	9% (4/44)	18% (45/246)	30% (22/73)
Weakness	End of	24% (9/37)	21% (46/221)	26% (18/69)
	Treatment			

P-value		0.08	0.36	0.64
0		16% (7/44)	16% (39/246)	21% (15/73)
Irritability	End of	32% (12/37)	15% (34/221)	16% (11/69)
	Treatment			
<i>P</i> -value		0.09	0.86	0.44
	0	11% (5/44)	25% (62/246)	34% (25/73)
Depression	End of	24% (9/37)	21% (46/221)	22% (15/69)
	Treatment			
P-value	•	0.06	0.23	0.02 🗸
	0	14% (6/44)	15% (38/246)	19% (14/73)
Itching	End of	27% (10/37)	14% (30/221)	19% (13/69)
	Treatment			
P-value		0.10	0.32	0.98
Changes in	0	14% (6/44)	17% (42/246)	23% (17/73)
Changes in	End of	30% (11/37)	17% (38/221)	16% (11/69)
Mood	Treatment			
P-value		0.04 个	0.92	0.27
	0	11% (5/44)	21% (52/246)	26% (19/73)
Heartburn	End of	19% (7/37)	19% (42/221)	23% (16/69)
	Treatment			
P-value		0.34	0.43	0.60
	0	7% (4/44)	14% (34/246)	30% (22/73)
Shortness	End of	35% (13/37)	14% (30/221)	22% (15/69)
of Breath	Treatment			
P-value	•	0.003 ↑	0.95	0.15
	0	5% (2/44)	11% (26/246)	22% (16/73)
Nausea	End of	8% (3/37)	16% (35/221)	28% (19/69)
	Treatment			
P-value	•	0.48	0.05	0.41
Diaman	0	16% (7/44)	18% (44/246)	21% (15/73)
Blurred	End of	19% (7/37)	15% (34/221)	15% (10/69)
Vision	Treatment			
P-value	•	0.71	0.42	0.36
Deserves	0	9% (4/44)	13% (32/246)	25% (18/73)
Decreased	End of	14% (5/37)	13% (29/221)	9% (6/69)
Appetite	Treatment			· · · · ·
<i>P</i> -value		0.53	0.97	0.009 ↓
	0	5% (2/44)	8% (19/246)	14% (10/73)
Diarrhea	End of	14% (5/37)	11% (24/221)	13% (9/69)
	Treatment	(-)-)	. , ,	x- <i>i i</i>

<i>P</i> -value		0.08	0.21	0.95
	0	9% (4/44)	15% (36/246)	21% (15/73)
Cough	End of	16% (6/37)	12% (27/221)	20% (14/69)
	Treatment			
P-value		0.32	0.43	0.95
	0	2% (1/44)	9% (23/246)	15% (11/73)
Chills	End of	16% (6/37)	11% (25/221)	23% (16/69)
	Treatment			
P-value		0.06	0.46	0.17
	0	2% (1/44)	9% (23/246)	22% (16/73)
Dizziness	End of	19% (7/37)	10% (22/221)	12% (8/69)
	Treatment			
P-value		0.04 个	0.86	0.09
Flu Like	0	9% (4/44)	7% (16/246)	11% (8/73)
Flu-Like	End of	5% (2/37)	11% (25/221)	17% (12/69)
Symptoms	Treatment			
P-value		0.43	0.05	0.21
	0	11% (5/44)	8% (20/246)	12% (9/73)
Rash	End of	15% (6/37)	7% (16/221)	10% (7/69)
	Treatment			
P-value		0.44	0.65	0.83
	0	5% (2/44)	6% (15/246)	12% (9/73)
Hair Loss	End of	8% (3/37)	10% (23/221)	17% (12/69)
	Treatment			
P-value		0.49	0.07	0.33
	0	5% (2/44)	4% (10/246)	7% (5/73)
Vomiting	End of	3% (1/37)	3% (7/221)	6% (4/69)
	Treatment			
P-value		0.68	0.48	0.77
	0	0% (0/44)	0% (0/246)	1% (1/73)
Anemia	End of	3% (1/37)	3% (6/221)	0% (0/69)
	Treatment			
P-value		Not tested	Not tested	Not tested
	0	0% (0/44)	3% (8/246)	7% (5/73)
Fever	End of	0% (0/37)	5% (12/221)	7% (5/69)
	Treatment			
P-value	•	Not tested	0.24	0.93

590 591

 \overline{a} – statistically significant *P*-value change shown in bold with arrow to indicate increase (\uparrow) or decrease (\downarrow) in symptom

91 ^b - data collected on 33 symptoms

592